Results 131 to 140 of about 22,482 (226)

Efficient Expression of Functionally Active Aflibercept with Designed N-glycans

Antibodies
Aflibercept is a therapeutic recombinant fusion protein comprising extracellular domains of human vascular endothelial growth factor receptors (VEGFRs) and IgG1-Fc.
Tahereh Keshvari, Stanislav Melnik, Lin Sun, Ali Niazi, F. Aram, Ali Moghadam, Benjamin Kogelmann, G. Wozniak-Knopp, Somanath Kallolimath, Amin Ramezani, H. Steinkellner   +10 more
semanticscholar   +1 more source

Switching to faricimab from aflibercept during maintenance treatment period for age-related macular degeneration

Scientific Reports
To compare the short-term treatment outcomes of aflibercept and faricimab for neovascular age-related macular degeneration (nAMD) during the maintenance treatment period, we included 82 eyes of 74 patients who switched from aflibercept to faricimab ...
Misa Masaoka, Kenji Yamashiro
doaj   +1 more source

Analytical and Functional Similarity of Aflibercept Biosimilar ABP 938 with Aflibercept Reference Product

Introduction ABP 938 is being developed as a biosimilar candidate to aflibercept reference product (RP), a biologic used for certain angiogenic eye disorders.
Shawn Cao, Ian N. Foltz, Scott Kuhns, Neungseon Seo, Mats Wikström, Jill Crouse-Zeineddini, Tian Wang, Kevin Kalenian, Jennifer Liu, Hyo S. Helen Chung, Xiaoyan Guan, Kelli Matthies, Michael Ng, Helen Y. Wong, Rupa Padaki   +14 more
core   +1 more source

Ranibizumab treatment history as predictor of the switch-response to aflibercept: evidence for drug tolerance

Clinical Ophthalmology, 2018
Ali Dirani, Irmela Mantel Department of Ophthalmology, University of Lausanne, Jules Gonin Eye Hospital, Fondation Asile des Aveugles, Lausanne, Switzerland Purpose: To investigate whether tolerance to the anti-VEGF drug, ranibizumab, develops after ...
Dirani A, Mantel I
doaj  

Risk of intraocular hemorrhage among exudative age-related macular degeneration patients treated with different anti-VEGF agents. [PDF]

PLoS One
Kim MS, Nam S, Lee J, Woo SJ.
europepmc   +1 more source

The efficacy and safety of aflibercept and conbercept in diabetic macular edema

, 2018
Siwei Cai, Qianhui Yang, Xiaorong Li, Yan Zhang Tianjin Medical University Eye Hospital, Tianjin Medical University Eye Institute, College of Optometry and Ophthalmology, Tianjin Medical University, Tianjin 300384, People’s Republic of China ...
Li X, Cai S, Zhang Y, Yang Q
core  

Faricimab 6 mg Versus Aflibercept 8 mg in Treatment-Naïve Neovascular Age-Related Macular Degeneration: A Protocol-Standardised In Silico Study. [PDF]

Pharmaceuticals (Basel)
Panos GD.
europepmc   +1 more source

Author Correction: Sustainability in medical retina: the environmental impact of using aflibercept 8 mg instead of aflibercept 2 mg in treatment-naïve patients with nAMD. [PDF]

Eye (Lond)
Bowley N, Thomas P, Sivaprasad S, Purbrick RMJ, Beardmore E, Gilbert R, Clarke A, Chase TJG.   +7 more
europepmc   +1 more source

Early intraocular pressure kinetics after intravitreal aflibercept 8 mg (0.07 mL) versus aflibercept 2 mg (0.05 mL) in nonglaucomatous eyes: a prospective comparative study. [PDF]

Int J Retina Vitreous
Licht A, Schneider A, Romanou V, Mirshahi A.   +3 more
europepmc   +1 more source

Efficacy and Safety of Aflibercept Biosimilars Relative to Reference Aflibercept Therapy for Neovascular Age-Related Macular Degeneration: A Systematic Review and Meta-Analysis

Clinical Ophthalmology
Hazem Saleh Aljuhani,1,* Rahaf A Hubayni,2,3,* Jumanah Qedair,2,3 Ziad M Bukhari,4 Ahmed Alzahrani,4 Razan Osama Bawazir,2,3 Orjwan Salah Badghaish,2,3 Faisal Alqahtani5 1Ophthalmology Department, Jeddah Eye Hospital, Jeddah, Saudi Arabia;
Aljuhani HS, Hubayni RA, Qedair J, Bukhari ZM, Alzahrani A, Bawazir RO, Badghaish OS, Alqahtani F   +7 more
doaj